AXSOME THERAPEUTICS INC (AXSM) Stock Overview
USA - NASDAQ:AXSM - US05464T1043 - Common Stock
AXSM Key Statistics, Chart & Performance
The current stock price of AXSM is 115.95 USD. In the past month the price decreased by -1.02%. In the past year, price increased by 20.98%.
AXSM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 46.56 | 711.73B | ||
| JNJ | JOHNSON & JOHNSON | 17.62 | 424.33B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 15.54 | 272.83B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.89 | 237.97B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 17.18 | 236.50B | ||
| MRK | MERCK & CO. INC. | 10.59 | 203.59B | ||
| PFE | PFIZER INC | 7.09 | 136.62B | ||
| SNY | SANOFI-ADR | 10.61 | 116.19B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.69 | 91.64B | ||
| GSK | GSK PLC-SPON ADR | 8.92 | 81.93B | ||
| ZTS | ZOETIS INC | 23.45 | 64.65B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 51.93 | 47.56B |
Related stock screener links
About AXSM
Company Profile
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. The company is headquartered in New York City, New York and currently employs 683 full-time employees. The company went IPO on 2015-11-19. The firm is focused on the development and commercialization of medicines for people living with central nervous system (CNS) conditions. The firm's commercial products include Auvelity, Sunosi and Symbravo. The company is also advancing a diversified, late-stage pipeline of product candidates for serious neurological and psychiatric conditions, which include AXS-05, Solriamfetol, AXS-12 and AXS-14. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. Symbravo (meloxicam and rizatriptan, 20 mg/10mg tablets) is an oral, single-dose medicine approved for the acute treatment of migraine with or without aura in adults.
Company Info
AXSOME THERAPEUTICS INC
One World Trade Center, 29Th Floor
New York City NEW YORK 10038 US
CEO: Herriot Tabuteau
Employees: 683
Phone: 12123323241
AXSOME THERAPEUTICS INC / AXSM FAQ
What is the stock price of AXSOME THERAPEUTICS INC today?
The current stock price of AXSM is 115.95 USD. The price decreased by -2.26% in the last trading session.
What is the ticker symbol for AXSOME THERAPEUTICS INC stock?
The exchange symbol of AXSOME THERAPEUTICS INC is AXSM and it is listed on the Nasdaq exchange.
On which exchange is AXSM stock listed?
AXSM stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for AXSOME THERAPEUTICS INC stock?
25 analysts have analysed AXSM and the average price target is 179.07 USD. This implies a price increase of 54.43% is expected in the next year compared to the current price of 115.95. Check the AXSOME THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is AXSOME THERAPEUTICS INC worth?
AXSOME THERAPEUTICS INC (AXSM) has a market capitalization of 5.79B USD. This makes AXSM a Mid Cap stock.
How many employees does AXSOME THERAPEUTICS INC have?
AXSOME THERAPEUTICS INC (AXSM) currently has 683 employees.
What are the support and resistance levels for AXSOME THERAPEUTICS INC (AXSM) stock?
AXSOME THERAPEUTICS INC (AXSM) has a support level at 115.28 and a resistance level at 125.17. Check the full technical report for a detailed analysis of AXSM support and resistance levels.
Is AXSOME THERAPEUTICS INC (AXSM) expected to grow?
The Revenue of AXSOME THERAPEUTICS INC (AXSM) is expected to grow by 60.98% in the next year. Check the estimates tab for more information on the AXSM EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy AXSOME THERAPEUTICS INC (AXSM) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of AXSM, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of AXSM, evaluating the profitability, health, valuation and growth aspects
- AXSOME THERAPEUTICS INC (AXSM) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- AXSOME THERAPEUTICS INC (AXSM) Sales and EPS estimates to see what analysts future expectations are.
- AXSOME THERAPEUTICS INC (AXSM) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- AXSOME THERAPEUTICS INC (AXSM) Insider and Institutional Ownership to learn about the owners and their transactions.
- AXSOME THERAPEUTICS INC (AXSM) Stock Chart to make your own analysis
- AXSOME THERAPEUTICS INC (AXSM) Latest news and press-releases to stay up to date.
Does AXSOME THERAPEUTICS INC (AXSM) stock pay dividends?
AXSM does not pay a dividend.
When does AXSOME THERAPEUTICS INC (AXSM) report earnings?
AXSOME THERAPEUTICS INC (AXSM) will report earnings on 2025-11-10, before the market open.
What is the Price/Earnings (PE) ratio of AXSOME THERAPEUTICS INC (AXSM)?
AXSOME THERAPEUTICS INC (AXSM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.07).
What is the Short Interest ratio of AXSOME THERAPEUTICS INC (AXSM) stock?
The outstanding short interest for AXSOME THERAPEUTICS INC (AXSM) is 8.49% of its float. Check the ownership tab for more information on the AXSM short interest.
AXSM Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to AXSM. When comparing the yearly performance of all stocks, AXSM is one of the better performing stocks in the market, outperforming 75.77% of all stocks.
AXSM Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to AXSM. Both the profitability and financial health of AXSM have multiple concerns.
AXSM Financial Highlights
Over the last trailing twelve months AXSM reported a non-GAAP Earnings per Share(EPS) of -5.07. The EPS increased by 22.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -38.59% | ||
| ROE | -337.87% | ||
| Debt/Equity | 2.62 |
AXSM Forecast & Estimates
25 analysts have analysed AXSM and the average price target is 179.07 USD. This implies a price increase of 54.43% is expected in the next year compared to the current price of 115.95.
For the next year, analysts expect an EPS growth of 37.43% and a revenue growth 60.98% for AXSM